| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study is to evaluate the effect of carbon ion radiotherapy and radiosensitization of cetuximab for head and neck squamous cell carcinoma. Clonogenic survival assay was done to evaluate enhancement effect of cetuximab to γ-ray and carbon ion. In HN5, cetuximab enhanced radiosensitivity to γ-ray and carbon ion. We performed western blotting to evaluate expression levels of phosphorylation-EGFR (p-EGFR) and EGFR after carbon ion radiotherapy with cetuximab in HN5. Neither cetuximab nor carbon ion showed any change on EGFR at short period from treatment. However, on p-EGFR, radiotherapy increase expression level and cetuximab suppressed this increase. Formation of nuclear γ-H2AX foci was monitored by immunofluorescence. Cetuximab differentially affected the survival and the radiosensitivity of HNSCC cells. Cetuximab suppressed DNA repair that was evident by the prolonged presence of nuclear γ-H2AX foci.
|
